Patents by Inventor Sunil Paliwal

Sunil Paliwal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLIC COMPOUNDS
    Publication number: 20230192720
    Abstract: The present application discloses compounds of Formula (I). Such compounds, pharmaceutically acceptable salts and compositions thereof, are inhibitors of Mcl-1 proteins and are useful in treating diseases and conditions characterized by excessive cellular proliferation such as cancer.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 22, 2023
    Inventors: Junhu Zhang, Peter Qinhua Huang, Kevin Duane Bunker, Sobhana Babu Boga, Sunny Abraham, Brant Clayton Boren, Wanlong Jiang, Sunil Paliwal
  • MACROCYCLIC COMPOUNDS
    Publication number: 20220144854
    Abstract: Disclosed are macrocyclic compounds of formula (I) comprising a 2-carboxy indole ring. Such compounds, and their pharmaceutically acceptable salts, are useful as Mcl-1 (myeloid cell leukemia-1) inhibitors. The compounds may be used in treating a disease or condition, such as cancer.
    Type: Application
    Filed: March 6, 2020
    Publication date: May 12, 2022
    Inventors: Junhu Zhang, Peter Qinhua Huang, Kevin Duane Bunker, Sobhana Babu Boga, Sunny Abraham, Brant Clayton Boren, Wanlong Jiang, Sunil Paliwal
  • Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones
    Patent number: 11261192
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: March 1, 2022
    Assignee: Recurium IP Holdings, LLC
    Inventors: Peter Qinhua Huang, Kevin Duane Bunker, Brant Clayton Boren, Sayee Gajanan Hegde, Hui Liu, Aditya Krishnan Unni, Sunny Abraham, Chad Daniel Hopkins, Sunil Paliwal
  • SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES
    Publication number: 20220024939
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: October 8, 2021
    Publication date: January 27, 2022
    Inventors: Peter Qinhua Huang, Kevin Duane Bunker, Brant Clayton Boren, Sayee Gajanan Hegde, Hui Liu, Aditya Krishnan Unni, Sunny Abraham, Chad Daniel Hopkins, Sunil Paliwal
  • 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS
    Publication number: 20210317124
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: June 15, 2021
    Publication date: October 14, 2021
    Inventors: Peter Qinhua Huang, Brant Clayton Boren, Kevin Duane Bunker, Hui Liu, Sunil Paliwal
  • L,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one analogs
    Patent number: 11124518
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: September 21, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Peter Qinhua Huang, Brant Clayton Boren, Kevin Duane Bunker, Hui Liu, Sunil Paliwal
  • SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES
    Publication number: 20210139482
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: February 26, 2019
    Publication date: May 13, 2021
    Inventors: Peter Qinhua Huang, Kevin Duane Bunker, Brant Clayton Boren, Sayee Gajanan Hegde, Hui Liu, Aditya Krishnan Unni, Sunny Abraham, Chad Daniel Hopkins, Sunil Paliwal
  • 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS
    Publication number: 20200157112
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: July 31, 2018
    Publication date: May 21, 2020
    Inventors: Peter Qinhua Huang, Brant Clayton Boren, Kevin Duane Bunker, Hui Liu, Sunil Paliwal
  • HYDROCHLORIDE SALTS OF 8-[{1-(3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXY}-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE AND PREPARATION PROCESS THEREFOR
    Publication number: 20190375751
    Abstract: Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.
    Type: Application
    Filed: January 9, 2019
    Publication date: December 12, 2019
    Applicant: OPKO Health, Inc.
    Inventors: Mengwei Hu, Sunil Paliwal, Neng-Yang Shih, Frank Bruno Guenter, Ingrid Mergelsberg
  • Hydrochloride salts of 8-[1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one and preparation process therefor
    Patent number: 10196394
    Abstract: Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: February 5, 2019
    Assignee: OPKO Health, Inc.
    Inventors: Mengwei Hu, Sunil Paliwal, Neng-Yang Shih, Frank Bruno Guenter, Ingrid Mergelsberg
  • NK 1 ANTAGONISTS
    Publication number: 20180215729
    Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 2, 2018
    Inventors: Anandan PALANI, Xianhai HUANG, Dong XIAO, Sunil PALIWAL, Hon-Chung TSUI, Michelle Laci WROBLESKI, Ashwin U. RAO, Cheng WANG, Sapna S. SHAH, Neng-Yang SHIH
  • Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
    Patent number: 10000493
    Abstract: This application discloses a process to synthesize 8-({1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-pheny-1,7-diazaspiro[4.5]decan-2-one comprising reacting a compound of the Formula 27a-sulfonate with zinc in the presence of acetic acid.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: June 19, 2018
    Assignee: OPKO Health, Inc.
    Inventors: Ingrid Mergelsberg, Dominik Hermann Scherer, Monika Erika Huttenloch, Hon-Chung Tsui, Sunil Paliwal, Neng-Yang Shih
  • NKantagonists
    Patent number: 9969711
    Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: May 15, 2018
    Assignee: OPKO Health, Inc.
    Inventors: Anandan Palani, Xianhai Huang, Dong Xiao, Sunil Paliwal, Hon-Chung Tsui, Michelle Laci Wrobleski, Ashwin U. Rao, Cheng Wang, Sapna S. Shah, Neng-Yang Shih
  • NK1 ANTAGONISTS
    Publication number: 20170283434
    Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
    Type: Application
    Filed: June 23, 2017
    Publication date: October 5, 2017
    Inventors: Sunil Paliwal, Gregory A. Reichard, Cheng Wang, Dong Xiao, Hon-Chung Tsui, Neng-Yang Shih, Juan D. Arredondo, Michelle Laci Wrobleski, Anandan Palani
  • NKantagonists
    Patent number: 9688693
    Abstract: A NK1 antagonist having the formula (I), wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: June 27, 2017
    Assignee: OPKO Health, Inc.
    Inventors: Sunil Paliwal, Gregory A. Reichard, Cheng Wang, Dong Xiao, Hon-Chung Tsui, Neng-Yang Shih, Juan D. Arredondo, Michelle Laci Wrobleski, Anandan Palani
  • NK 1 ANTAGONISTS
    Publication number: 20170029403
    Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
    Type: Application
    Filed: October 14, 2016
    Publication date: February 2, 2017
    Inventors: Anandan Palani, Xianhai Huang, Dong Xiao, Sunil Paliwal, Hon-Chung Tsui, Michelle Laci Wrobleski, Ashwin U. Rao, Cheng Wang, Sapna S. Shah, Neng-Yang Shih
  • PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE COMPOUNDS
    Publication number: 20170008893
    Abstract: This application discloses a process to synthesize 8-({1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-pheny-1,7-diazaspiro[4.5]decan-2-one comprising reacting a compound of the Formula 27a-sulfonate with zinc in the presence of acetic acid.
    Type: Application
    Filed: February 12, 2016
    Publication date: January 12, 2017
    Inventors: Ingrid Mergelsberg, Dominik Hermann Scherer, Monika Erika Huttenloch, Hon-Chung Tsui, Sunil Paliwal, Neng-Yang Shih
  • NKantagonists
    Patent number: 9469629
    Abstract: A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: October 18, 2016
    Assignee: OPKO Health, Inc.
    Inventors: Anandan Palani, Xianhai Huang, Dong Xiao, Sunil Paliwal, Hon-Chung Tsui, Michelle Laci Wrobleski, Ashwin U. Rao, Cheng Wang, Sapna S. Shah, Neng-Yang Shih
  • Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
    Patent number: 9260428
    Abstract: This application discloses a process to synthesize 8-({1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-pheny-1.7-diaza-spiro[4.5]decan-2-one comprising reacting a compound of the Formula 27a-sulfonate with zinc in the presence of acetic acid.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: February 16, 2016
    Assignee: OPKO Health, Inc.
    Inventors: Ingrid Mergelsberg, Dominik Hermann Scherer, Monika Erika Huttenloch, Hon-Chung Tsui, Sunil Paliwal, Neng-Yang Shih
  • Amidopyrazole inhibitors of interleukin receptor-associated kinases
    Patent number: 9169260
    Abstract: This invention relates to amidopyrazole compounds that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment of cellular proliferative diseases, for example, cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: October 27, 2015
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: William T. McElroy, Guoqing Li, Ginny Dai Ho, Zheng Tan, Sunil Paliwal, William Michael Seganish, Deen Tulshian, John Lampe, Joey L. Methot, Hua Zhou, Michael D. Altman, Liang Zhu